Decreased expression of eukaryotic initiation factor 3f is an adverse prognostic factor for stage I-III gastric cancer

World Journal of Surgical Oncology

Volumn 12, Issue 1, 2014, Pages

  Li, Guanghua ^b   Wang, Na ^a   Sun, Chuanjin ^a   Li, Bo ^a  

^a People's Hospital of Zhangqiu   (China)

^b THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

Biomarker; eIF3f; Gastric cancer; Prognosis

Indexed keywords

EUKARYOTIC INITIATION FACTOR 3F; INITIATION FACTOR 3; UNCLASSIFIED DRUG; INITIATION FACTOR 3F; EIF3F PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STOMACH CANCER; TUMOR DIFFERENTIATION; VERY ELDERLY; HISTOPATHOLOGY; ADENOCARCINOMA; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; STOMACH; STOMACH NEOPLASMS; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; EUKARYOTIC INITIATION FACTOR-3; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; STOMACH; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84902000070     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-12-72     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2013, 61:69-90.
2. Batista TP, Santos CA, Almeida GF. Perioperative chemotherapy in locally advanced gastric cancer. Arq Gastroenterol 2013, 50:236-242. 10.1590/S0004-28032013000200042, 24322198.
3. Xiao JW, Chen JH, Ren MY, Tian XB, Wang CS. Relationship between expression of gastrokine 1 and clinicopathological characteristics in gastric cancer patients. Asian Pac J Cancer Prev 2012, 13:5897-5901. 10.7314/APJCP.2012.13.11.5897, 23317277.
4. Xu X, Yang X, Xing C, Zhang S, Cao J. miRNA: the nemesis of gastric cancer (Review). Oncol Lett 2013, 6:631-641. 3789097, 24137382.
5. Juca PC, Lourenco L, Kesley R, Mello EL, Oliveira IM, Correa JH. Comparison of survival and prognostic factors in patients with gastric adenocarcinoma in T2 and T3. Rev Col Bras Cir 2012, 39(5):377-384. 10.1590/S0100-69912012000500007, 23174788.
6. Xing X, Tang Y, Yuan G, Wang Y, Wang J, Yang Y, Chen M. The prognostic value of E-cadherin in gastric cancer: a meta-analysis. Int J Cancer 2013, 132(11):2589-2596. 10.1002/ijc.27947, 23169395.
7. Hu BS, Hu H, Zhu CY, Gu YL, Li JP. Overexpression of GOLPH3 is associated with poor clinical outcome in gastric cancer. Tumour Biol: J Int Soc Oncodev Biol Med 2013, 34(1):515-520.
8. Pan XF, Xie Y, Loh M, Yang SJ, Wen YY, Tian Z, Huang H, Lan H, Chen F, Soong R, Yang CX. Polymorphisms of XRCC1 and ADPRT genes and risk of noncardia gastric cancer in a Chinese population: a case-control study. Asian Pac J Cancer Prev 2012, 13(11):5637-5642. 10.7314/APJCP.2012.13.11.5637, 23317230.
9. Xiao H, Xu LH, Yamada Y, Liu DX. Coronavirus spike protein inhibits host cell translation by interaction with eIF3f. PLoS One 2008, 3(1):e1494. 10.1371/journal.pone.0001494, 2204050, 18231581.
10. Masutani M, Sonenberg N, Yokoyama S, Imataka H. Reconstitution reveals the functional core of mammalian eIF3. EMBO J 2007, 26(14):3373-3383. 10.1038/sj.emboj.7601765, 1933396, 17581632.
11. Shi J, Kahle A, Hershey JW, Honchak BM, Warneke JA, Leong SP, Nelson MA. Decreased expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells. Oncogene 2006, 25(35):4923-4936. 10.1038/sj.onc.1209495, 16532022.
12. Wen F, Zhou R, Shen A, Choi A, Uribe D, Shi J. The tumor suppressive role of eIF3f and its function in translation inhibition and rRNA degradation. PLoS One 2012, 7(3):e34194. 10.1371/journal.pone.0034194, 3311619, 22457825.
13. Moretti J, Chastagner P, Gastaldello S, Heuss SF, Dirac AM, Bernards R, Masucci MG, Israel A, Brou C. The translation initiation factor 3f (eIF3f) exhibits a deubiquitinase activity regulating Notch activation. PLoS Biol 2010, 8(11):e1000545. 10.1371/journal.pbio.1000545, 2990700, 21124883.
14. Jiang B, Zhang B, Liang P, Song J, Deng H, Tu Z, Deng G, Xiao X. Nucleolin/C23 mediates the antiapoptotic effect of heat shock protein 70 during oxidative stress. FEBS J 2010, 277(3):642-652. 10.1111/j.1742-4658.2009.07510.x, 20050922.
15. Ray A, Bandyopadhyay A, Matsumoto T, Deng H, Maitra U. Fission yeast translation initiation factor 3 subunit eIF3h is not essential for global translation initiation, but deletion of eif3h + affects spore formation. Yeast 2008, 25(11):809-823. 10.1002/yea.1635, 19061185.
16. Doldan A, Chandramouli A, Shanas R, Bhattacharyya A, Leong SP, Nelson MA, Shi J. Loss of the eukaryotic initiation factor 3f in melanoma. Mol Carcinog 2008, 47(10):806-813. 10.1002/mc.20436, 2635928, 18381585.
17. Marchione R, Leibovitch SA, Lenormand JL. The translational factor eIF3f: the ambivalent eIF3 subunit. Cell Mol Life Sci 2013, 70:3603-3616. 10.1007/s00018-013-1263-y, 3771369, 23354061.
18. Shi J, Hershey JW, Nelson MA. Phosphorylation of the eukaryotic initiation factor 3f by cyclin-dependent kinase 11 during apoptosis. FEBS Lett 2009, 583(6):971-977. 10.1016/j.febslet.2009.02.028, 2666973, 19245811.
19. Doldan A, Chandramouli A, Shanas R, Bhattacharyya A, Cunningham JT, Nelson MA, Shi J. Loss of the eukaryotic initiation factor 3f in pancreatic cancer. Mol Carcinog 2008, 47(3):235-244. 10.1002/mc.20379, 2568992, 17918192.
20. Higareda-Mendoza AE, Pardo-Galvan MA. Expression of human eukaryotic initiation factor 3f oscillates with cell cycle in A549 cells and is essential for cell viability. Cell Division 2010, 5:10. 10.1186/1747-1028-5-10, 2877012, 20462454.
21. Kwon SJ. Evaluation of the 7th UICC TNM staging system of gastric cancer. J Gastric Cancer 2011, 11(2):78-85. 10.5230/jgc.2011.11.2.78, 3204489, 22076207.
22. Hadi R, Mohanti BK, Pathy S, Rath GK, Shukla NK, Deo SV, Sharma A, Raina V. Gastric cancer: a retrospective analysis from AIIMS, New Delhi. Gulf J Oncolog 2012, 1(12):11-16.
23. Zagouri F, Papadimitriou CA, Dimopoulos MA, Pectasides D. Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review. Cancer Treat Rev 2011, 37(8):599-610. 10.1016/j.ctrv.2011.03.007, 21676549.
24. Fujitani K, Yamada M, Hirao M, Kurokawa Y, Tsujinaka T. Optimal indications of surgical palliation for incurable advanced gastric cancer presenting with malignant gastrointestinal obstruction. Gastric Cancer 2011, 14(4):353-359. 10.1007/s10120-011-0053-1, 21559861.
25. D'Ugo D, Persiani R, Zoccali M, Cananzi F, Vigorita V, Mazzeo P, Tufo A, Biondi A. Surgical issues after neoadjuvant treatment for gastric cancer. Eur Rev Med Pharmacol Sci 2010, 14(4):315-319.
26. Valente ST, Gilmartin GM, Mott C, Falkard B, Goff SP. Inhibition of HIV-1 replication by eIF3f. Proc Natl Acad Sci USA 2009, 106(11):4071-4078. 10.1073/pnas.0900557106, 2646627, 19237569.